Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S6
FBXW7-mediated ERK3 degradation regulates the proliferation of lung cancer cells.
An HJ et al.
Experimental & Molecular Medicine, 2022
Biochemical, cellular and structural characterization of novel and selective ERK3 inhibitors.
Grädler U et al.
Bioorganic & Medicinal Chemistry Letters, 2020
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.
Schrader A et al.
Nature Communications, 2018
29449575 (PubMed )
Supplement: 41467_2017_2688_MOESM20_ESM.xlsx › d__Freq_TP093
L290P/V mutations increase ERK3's cytoplasmic localization and migration/invasion-promoting capability in cancer cells.
Alsaran H et al.
Scientific Reports, 2017
XomAnnotate: Analysis of Heterogeneous and Complex Exome- A Step towards Translational Medicine.
Talukder AK et al.
Plos One, 2015
25905921 (PubMed )
Supplement: pone.0123569.s008.xls › BC7_ERR166315
Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.
Marks JL et al.
Plos One, 2007
17487277 (PubMed )
Supplement: pone.0000426.s004.doc
Select a paper to view details